Acute promyelocytic leukemia: Difference between revisions
Category |
No edit summary |
||
Line 16: | Line 16: | ||
'''For patient information click [[Leukemia (patient information)|here]]''' | '''For patient information click [[Leukemia (patient information)|here]]''' | ||
{{CMG}} | {{CMG}}; {{GRR}} {{Nat}} | ||
{{SK}} Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant | {{SK}} Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant |
Revision as of 16:11, 8 April 2019
Template:DiseaseDisorder infobox
Acute promyelocytic leukemia Microchapters |
Differentiating Acute promyelocytic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Acute promyelocytic leukemia On the Web |
American Roentgen Ray Society Images of Acute promyelocytic leukemia |
Directions to Hospitals Treating Acute promyelocytic leukemia |
Risk calculators and risk factors for Acute promyelocytic leukemia |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Grammar Reviewer: Natalie Harpenau, B.S.[2]
Synonyms and keywords: Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Acute promyelocytic leukemia from Other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Other Imaging studies | Other Diagnostic Studies
Treatment
Medical Therapy | Cost-Effectiveness of Therapy | Future or Investigational Therapies